Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment

This study has been terminated.
(did not apply for ethics renewal)
Information provided by (Responsible Party):
AHS Cancer Control Alberta Identifier:
First received: August 17, 2005
Last updated: June 27, 2012
Last verified: June 2012

For many years scientists and cancer researchers have been trying to find out why some people benefit more from anti-cancer medications than other people who receive the same amount and same kind of medications. Current studies suggest that inherited characteristics might explain these differences. Height and eye color are examples of characteristics that have been inherited from parents. Studies suggest that people might also inherit genetic differences in how their bodies break down medications. When a person receives an anti-cancer medication, it is broken down by the liver into smaller parts or by-products. To try to understand more about how people's bodies break down anti-cancer medications, the researchers are studying the by-products (called metabolites) of epirubicin in the blood of people who are taking this medication as part of their breast cancer treatment.

Condition Intervention
Breast Cancer
Drug: FEC 100

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 Using Epirubicin Clearance and the Ratios of Epirubicin and Epirubicinol Glucuronide to Epirubicin

Resource links provided by NLM:

Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 120
Study Start Date: January 2002
Estimated Study Completion Date: January 2013
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: FEC 100
    5-fluoruracil, epirubicin and cyclophosphamide every three weeks for six treatments
  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cross Cancer Clinic patients


Inclusion Criteria:

  • Receiving adjuvant or neoadjuvant FEC100

Exclusion Criteria:

  • Elevated bilirubin
  • Abnormal liver or kidney function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00131612

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Principal Investigator: Michael Sawyer, MD AHS Cancer Control Alberta
  More Information

No publications provided

Responsible Party: AHS Cancer Control Alberta Identifier: NCT00131612     History of Changes
Other Study ID Numbers: BR-01-0031 / 17027
Study First Received: August 17, 2005
Last Updated: June 27, 2012
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
adjuvant therapy
uridine glucuronosyl/transferase 2B7

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases processed this record on February 27, 2015